Dear reader, in only a few years, an American startup evolved from a simple platform selling hair-loss treatments into one of the most prominent models in global digital health. That company is Hims & Hers, founded in 2017. It expanded rapidly, with 2025 revenue exceeding two and a third billion dollars, growth approaching 60%, and more than 2.5 million subscribers. Yet the most important story is not only in the numbers. It lies in the major bet the company is making on its future: artificial intelligence.

Hims & Hers is a direct-to-consumer healthcare platform built on a simple but powerful idea: moving a large part of routine medical care from the clinic to the phone. Through the platform, users can connect with licensed clinicians online, receive digital prescriptions, and have medication delivered to their doorstep by a cloud pharmacy.

The company covers multiple areas, including sexual health, hair loss, hormones, weight loss, dermatology, and mental health. It has also recently added at-home laboratory testing. Since its founding, the platform has conducted more than fifty million medical consultations and expanded across the United States, Canada, the United Kingdom, and several European markets. At its core, the idea is to make healthcare easier, faster, more private, and increasingly personalized to everyone’s needs.

In 2025, the company made it clear that its future would be built around artificial intelligence. This was not simply a marketing slogan. It was a strategic message, reinforced by the appointment of Mo Elshenawy as chief technology officer. Elshenawy, formerly the chief technology officer of Cruise, the autonomous vehicle company, brings more than twenty years of experience in artificial intelligence and large-scale technical infrastructure.

The company then sent an even stronger signal to the market by raising approximately 870 million dollars through convertible notes, with proceeds allocated to developing AI tools, building data infrastructure, and improving personalized treatment algorithms. The declared vision is to connect all parts of the care journey into a single continuous chain: from data collection to understanding the condition to proposing the treatment pathway to prescribing medication, delivering it, and monitoring outcomes.

What makes the Hims & Hers story important is that its AI strategy extends beyond public statements. It is beginning to turn into practical tools. One of the most prominent is MedMatch, a system that uses machine learning to help guide patients toward the treatment pathway most appropriate for their condition. The company aims to broaden the system and improve its accuracy so it can support more personalized treatment decisions over time.

The company has also developed an AI agent to interpret lab results. This tool can read a user’s biomarkers and present personalized health insights in clear, accessible language. Importantly, the company says this tool does not diagnose disease, does not replace the physician, and does not draw answers from the open internet. Instead, it relies on a dedicated medical knowledge base developed with specialists, while maintaining the company’s stated commitment to protecting user privacy.

Here lies the delicate point: in this model, AI is not presented as a replacement for the doctor, but as an assisting layer between data and medical decision-making. Used well, it may save time, reduce confusion, and better align care with patient needs.

The secret of the strategy is not the application alone. It lies in what can be called the data flywheel. As the number of subscribers grows, the company accumulates larger volumes of health, behavioral, and treatment data. As the data grows, AI models become more capable of personalization and prediction. As personalization improves, the platform becomes more attractive to new users. The wheel then turns faster: more users, more data, better algorithms, more personalized experiences, and faster growth.

Vertical integration strengthens this flywheel. The company does not stop at telehealth consultation. It brings together the clinician, the prescription, the pharmacy, at-home lab testing, and delivery. This integration gives it greater control over user experience, quality, and cost, while also feeding the model with data at every step of the care journey. Hims & Hers is therefore not merely building a consultation platform; it is trying to build a relatively closed digital health ecosystem centered around the user from the first question to the final dose.

The company does not appear satisfied with its domestic market. In 2026, it is moving into new therapeutic categories and expanding globally through acquisitions and growth in Europe, Australia, and Canada. It has also announced an ambitious 2030 goal: at least 6.5 billion dollars in annual revenue.

On June 2, 2026, Hims & Hers announced the completion of its acquisition of Eucalyptus, the Australian company behind brands such as Juniper, Pilot, and Kin. This expanded its presence across Australia, Canada, Germany, Japan, and the United Kingdom, and marked its official entry into the Australian market, following earlier acquisitions of ZAVA and Livewell and a growing presence in parts of Europe.

The larger dream of its founder, Andrew Dudum, is to make Hims & Hers the leading global platform in consumer health: a platform that enables every person to access care designed for them, wherever they are, through a mix of artificial intelligence, local medical expertise, and digital convenience. It is an appealing vision because it promises to shift healthcare from a system that waits for patients in clinics to one that reaches them through their phones and homes.

The road, however, is not free of risk. The company faces growing regulatory scrutiny, especially after controversy surrounding weight-loss medications and the end of its partnership with Novo Nordisk. Introducing AI into medicine also raises difficult questions. Will algorithmic recommendations always be accurate and safe? Who bears responsibility when something goes wrong? How will highly sensitive health data be protected? Does the user always know when they are interacting with a clinician, an AI system, or content shaped by commercial incentives?

AI-powered personalization may sometimes be real care. At other times, it may become advanced marketing dressed in the language of science. Distinguishing between the two is not easy. It is a shared responsibility among the company, the clinician, the user, and regulators. Medicine is not built on speed alone, nor on access alone. It is built on trust, safety, transparency, and evidence.

To be fair, the promise is significant. Digital platforms can close genuine gaps in access to care, particularly for routine conditions, chronic follow-up, and ongoing management. Yet they may also create new gaps if the medical relationship becomes a fast consumer experience, or if treatment decisions are driven by algorithms whose limits patients do not understand.

In the end, Hims & Hers offers a clear window into one possible form of tomorrow’s medicine: digital, proactive, personalized, guided by algorithms, and powered by data from millions of users. But the success of this model will not be measured only by subscriber growth or revenue. It will be measured by its ability to earn trust, protect patients, and deliver safe care, rather than by merely providing an attractive technology experience.

In our region, where gaps in access to care remain significant, this model could represent an opportunity for a major leap if it is well-regulated and adapted locally. But the most important condition is that we remember that behind every data point is a human being, and behind every algorithmic recommendation is a decision that may affect health and life. The digital clinic may be the future of medicine, but it must remain a clinic first, not a smart store wearing a doctor’s coat.